Regeneron Pushes Bispecifics Into MZL and AL Amyloidosis Without Pivotal Numbers
Clinical Trial Updates

Regeneron Pushes Bispecifics Into MZL and AL Amyloidosis Without Pivotal Numbers

Published : 20 Nov 2026

The Overview
Regeneron Pharmaceuticals announced new and updated data from its hematology portfolio and pipeline will be presented across 14 abstracts at the American Society of Hematology (ASH) 2026 Annual Meeting in New Orleans from December 12-15. Key presentations include potentially pivotal, first-in-class data for Ordspono (odronextamab), a CD20xCD3 bispecific antibody, in patients with relapsed or refractory marginal zone lymphoma (MZL). Additionally, longer-term results and biomarker analysis for Lynozyfic (linvoseltamab), a BCMAxCD3 bispecific antibody, in relapsed or refractory systemic light chain (AL) amyloidosis will be shared. The company will also highlight data for Lynozyfic in multiple myeloma and early clinical research for novel siRNA therapies in blood disorders, alongside an analysis of cemdisiran and pozelimab in paroxysmal nocturnal hemoglobinuria (PNH).
Knolens Analysis

Regeneron will test whether an EMA-approved CD20xCD3 platform can stretch into marginal zone lymphoma when it presents potentially pivotal first-in-class odronextamab data in relapsed or refractory MZL among 14 abstracts at ASH 2026 in New Orleans on December 12-15. The mechanistic bet is supported because epcoritamab achieved 59% ORR with 41% CR at 37 months median follow-up in relapsed or refractory DLBCL and 82% ORR with 63% CR in relapsed or refractory FL, while glofitamab achieved 52% objective response with 39% CR, and mosunetuzumab achieved 59% ORR with 45% CR in transplant-ineligible DLBCL, all as single-arm Phase 1/2 or Phase 2 datasets. [1] Odronextamab itself received EU approval on 26 August 2024 as monotherapy for relapsed or refractory FL or DLBCL after two or more lines on ELM-1 and ELM-2. [2] Payer risk is already visible because additional benefit was found not proven for odronextamab in FL and DLBCL and for linvoseltamab in multiple myeloma, and axi-cel versus mosunetuzumab in third-line plus FL carried an ICER of $108,307 per QALY gained. [3] No MZL response, durability, CRS or ICANS figures are stated, STARGLO showed FDA can reject an OS-positive glofitamab combination over geographic representativeness, and prior bendamustine was shown to reduce glofitamab PFS, leaving the MZL claim mechanistically plausible but regulatorily and commercially unproven. [1]

CD20xCD3 activity proven in DLBCL/FL and ELM-1/ELM-2 approval, but no MZL ORR/CR/PFS or safety figures stated for ASH 2026. [4]

At a Glance
IndicationRelapsed or refractory marginal zone lymphoma (MZL)
DrugOdronextamab
Mechanism of ActionCD20xCD3 bispecific antibody
CompanyRegeneron Pharmaceuticals, Inc.
Trial PhasePhase 2
Trial AcronymELM-2
CategoryClinical Trial Event
Sub CategoryTopline Results Positive
Therapeutic AreaHematology
Conference NameAmerican Society of Hematology (ASH)
Meeting DatesDecember 12-15, 2026
Meeting LocationNew Orleans
Total Abstracts14
Key Drug 2Linvoseltamab
Key Drug 2 MOABCMAxCD3 bispecific antibody
Combination DrugCemdisiran and Pozelimab
Combination Drug IndicationParoxysmal Nocturnal Hemoglobinuria
Ordspono EU Approved IndicationR/R FL or DLBCL after two or more lines of systemic therapy
Lynozyfic Approved IndicationR/R Multiple Myeloma (US: after 4 lines, EU: after at least 3 prior therapies)

Regeneron to Present Key Hematology Data at ASH 2026

Regeneron Pharmaceuticals announced new and updated data from its hematology portfolio and pipeline will be presented across 14 abstracts at the American Society of Hematology (ASH) 2026 Annual Meeting in New Orleans from December 12-15. Key presentations include potentially pivotal, first-in-class data for Ordspono (odronextamab), a CD20xCD3 bispecific antibody, in patients with relapsed or refractory marginal zone lymphoma (MZL). Additionally, longer-term results and biomarker analysis for Lynozyfic (linvoseltamab), a BCMAxCD3 bispecific antibody, in relapsed or refractory systemic light chain (AL) amyloidosis will be shared. The company will also highlight data for Lynozyfic in multiple myeloma and early clinical research for novel siRNA therapies in blood disorders, alongside an analysis of cemdisiran and pozelimab in paroxysmal nocturnal hemoglobinuria (PNH).

  • Ordspono's Pivotal Data in MZL: Regeneron will present primary results from the ELM-2 trial for Ordspono (odronextamab) in relapsed or refractory marginal zone lymphoma (MZL). This dataset is described as potentially registrational and first-in-class, addressing a significant unmet need for patients with this blood cancer. Ordspono is a CD20xCD3 bispecific antibody designed to activate T-cells against cancer cells.
  • Lynozyfic's Extended Efficacy in AL Amyloidosis and MM: Longer-term data and biomarker analysis from the Phase 1/2 LINKER-AL2 trial for Lynozyfic (linvoseltamab) in relapsed or refractory systemic light chain (AL) amyloidosis will be shared, building on previously reported efficacy. Additionally, a post-hoc analysis from the Phase 2 LINKER-MM1 trial will highlight treatment-free remission rates for Lynozyfic in relapsed/refractory multiple myeloma.
  • Diverse Pipeline Advancements: The presentations also include an analysis of combination therapy with cemdisiran and pozelimab (cemdi-poze) in paroxysmal nocturnal hemoglobinuria (PNH), examining lactate dehydrogenase normalization and transfusion avoidance. Furthermore, Regeneron will share early clinical research for its novel siRNA therapies targeting various blood disorders, showcasing the breadth of its hematology pipeline.

Why New Options are Crucial for Relapsed/Refractory MZL

Relapsed or refractory marginal zone lymphoma (MZL) remains difficult to manage because MZL is a heterogeneous B-cell malignancy for which no standard treatment exists, and its relative rarity has largely precluded adoption of a single management strategy. Outcomes for MZL and follicular lymphoma remain suboptimal, owing to the limited number of approved agents and the incurable nature of the diseases.

  • Limited and variable options beyond frontline: Among 526 patients with relapsed/refractory MZL who received a second or third line of therapy between 1 January 2014 and 31 December 2021, most patients received chemoimmunotherapy (42.8%), Bruton's tyrosine kinase inhibitors (25.1%), or lenalidomide and rituximab/obinutuzumab (16.3%) in second line, with treatment patterns varied across subtypes.

  • Toxicity-driven discontinuation and intolerance: One in five patients quit treatment with ibrutinib because of harmful side effects, including increased risk of bleeding, atrial fibrillation and high blood pressure thought to be caused by ibrutinib blocking other proteins besides BTK. In previously treated MZL treated with 560 mg ibrutinib orally once daily, grade ≥3 adverse events (>5%) included anemia, pneumonia, and fatigue, serious adverse events of any grade occurred in 44%, and rates of discontinuation and dose reductions due to adverse events were 17% and 10%, respectively.

  • Added toxicity of combination approaches: In Japanese patients with relapsed/refractory indolent non-Hodgkin lymphoma, grade 3/4 adverse events were more frequent with lenalidomide plus rituximab (67%) than with rituximab plus placebo (22%), primarily attributable to increased neutropenia (50% vs 17%). With lenalidomide, rituximab, and ibrutinib in previously untreated follicular lymphoma and MZL, grade 3-4 adverse events were observed in 64.6%, including 50% with grade 3-4 rash.

  • Acquired resistance to BTK inhibition: Resistance to covalent BTK inhibitors most commonly develops through BTK C481 substitutions and activating PLCG2 mutations. Acquired resistance mutations PLCG2 (R665W/R742P) and BTK (C481Y/C481F) were detected in 2 patients whose disease progressed on zanubrutinib, and a BTK E41K noncatalytic activating mutation was identified before treatment in 1 patient who was zanubrutinib-refractory.

  • Transformation and prognostic stratification gaps: Marginal zone lymphoma and lymphoplasmacytic lymphoma may undergo transformation events, most commonly to diffuse large B-cell lymphoma, with median time from indolent lymphoma diagnosis to transformed diffuse large B-cell lymphoma of 35 months (range, 14-53 months) and 5-year overall survival and progression-free survival rates after histological transformation of 50% and 26%, respectively. The MZL-international prognostic index remains the principal basis for risk stratification; however, its differentiation power is limited, particularly for intermediate-risk groups, and TP53 mutations are closely associated with histological transformation and high-risk outcomes.

Ordspono's Pivotal ELM-2 Data in Relapsed/Refractory MZL

Recent studies in relapsed or refractory marginal zone lymphoma (MZL) have evaluated targeted, chemotherapy-free interventions including non-covalent and next-generation Bruton tyrosine kinase inhibitors, PI3K inhibition, and glycoengineered anti-CD20 combinations. These trials report high overall response rates with durable disease control and distinct tolerability profiles across heavily pretreated populations.

Study Intervention Key Efficacy Outcomes Key Safety Outcomes
BRUIN Phase 1/2 Study (NCT03740529) Pirtobrutinib in 36 R/R MZL patients (EMZL: n=6; NMZL: n=17; SMZL: n=13) ORR was 55.6% (95% CI, 38.1-72.1) including 3 (8.3%) complete responses and 17 (47.2%) partial responses; median DOR was 17.8 months (95% CI, 7.4-non-estimable [NE]); median PFS was 16.6 months (95% CI, 9.0-22.1); with median follow-up of 32.4 months (IQR, 28.0, 41.3), median OS was NE (95% CI, 29.5-NE); ORR for patients with prior cBTKi therapy was 53.8% (95% CI, 33.4-73.4) Dose reductions in 4 patients (11.1%) and permanent discontinuation due to TEAEs in 4 (11.1%)
MAGNOLIA Trial (BGB-3111-214) Zanubrutinib in 68 patients with R/R MZL IRC-assessed ORR was 68.2% and complete response (CR) was 25.8%; ORR by investigator assessment was 74.2%, and CR rate was 25.8%; median DOR and median PFS by independent review was not reached; IRC-assessed DOR rate at 12 months was 93.0%, and IRC-assessed PFS rate was 82.5% at both 12 and 15 months Most common AEs were diarrhea (22.1%), contusion (20.6%), and constipation (14.7%); atrial fibrillation/flutter was reported in 2 patients; 1 patient had grade 3 hypertension; no patient experienced major hemorrhage; 4 patients discontinued treatment due to AEs, none of which were considered treatment-related
CHRONOS-1 Study Part B (#NCT01660451) IV copanlisib 60 mg on days 1, 8, and 15 of 28-day cycles in 23 patients with relapsed/refractory MZL Objective response rate was 78.3% (18/23; 3 complete responses and 15 partial responses); median duration of response was 17.4 months (median follow-up, 9.4 months); median time to response was 2.1 months; median progression-free survival was 24.1 months (median follow-up, 10.3 months); median overall survival was not reached (median follow-up, 28.4 months) Most common all-grade TEAEs included fatigue (52.2%, 12/23), diarrhea, and transient, infusion-related hyperglycemia (each 47.8%, 11/23); 19 patients (82.6%) had grade 3/4 TEAEs, most commonly transient, infusion-related hyperglycemia and hypertension (each 39.1%, 9/23); TEAEs led to dose reduction or dose interruptions/delays in 9 patients (39.1%) and 18 patients (78.3%), respectively
Multicentre Single-Arm Phase 1b/2 Trial (NCT04110301) MIL62 1000 mg combined with lenalidomide in patients with R/R follicular lymphoma or MZL 43 patients (86%, 95% CI: 73, 94) achieved objective response; disease control rate was 96% (48/50, 95% CI: 86, 100); proportion of patients with DoR > 6 months was 77% (33/43); 1-year progression-free survival rate was 72% (95% CI: 57, 83); 9-month DoR rate was 74% (95% CI: 58, 85); 1-year overall survival rate was 98% (95% CI: 85, 100) Most common TRAEs were neutropenia (93%, 50/54), leukopenia (85% 46/54), thrombocytopenia (61% 33/54), lymphopenia (32% 17/54), and alanine aminotransferase increased (20% 11/54)

Understanding Ordspono's Safety Across Lymphoma Indications

Odronextamab, a hinge-stabilised, fully human IgG4-based CD20 × CD3 bispecific antibody that binds CD3 on T cells and CD20 on B cells, activates T-cells leading to release of multiple cytokines and potentially to cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). Published data from ELM-1 and ELM-2 describe a generally manageable safety profile with supportive care, with CRS predominantly low grade and mitigation by step-up dosing in cycle 1.

  • In ELM-1 in 145 heavily pretreated patients with median of 3 (IQR 2-5] previous therapies, no dose-limiting toxicities were observed up to the maximum dose of 320 mg once per week, and cytokine release syndrome and neurological treatment-emergent adverse events were predominantly low grade and did not result in treatment discontinuation.

  • The most common grade 3 or worse treatment-emergent adverse events in ELM-1 were anaemia (36 [25%]), lymphopenia (28 [19%]), hypophosphataemia (27 [19%]), neutropenia (27 [19%]), and thrombocytopenia (20 [14%]), with serious treatment-emergent adverse events in 89 (61%) of 145 patients, most frequent were cytokine release syndrome (41 [28%]), pyrexia (11 [8%]), pneumonia (nine [6%]), and infusion-related reaction (six [4%]), and four deaths considered related to treatment (gastric perforation in a patient with gastric involvement by lymphoma, lung infection, pneumonia, and tumour-lysis syndrome).

  • In ELM-2 in relapsed/refractory follicular lymphoma in 128 patients evaluated, discontinuation of odronextamab due to adverse events occurred in 16% of patients, and the most common treatment-emergent adverse events were cytokine release syndrome [56%; grade ≥3 1.7% (1/60) with 0.7/4/20 mg step-up], neutropenia (39%), and pyrexia (38%).

  • In ELM-2 in relapsed/refractory diffuse large B-cell lymphoma in 127 patients, with a step-up of 0.7 to 4 to 20 mg (n = 60), CRS was the most common treatment-emergent adverse event (53.3% (grade ≥3, 1.7%)), no immune effector cell-associated neurotoxicity syndrome was reported, and infections were reported in 82/127 (64.6%) patients (grade ≥3, 38.6%; coronavirus disease 2019, 18.1% (grade ≥3, 12.6%)).

  • Across CD20 × CD3 bispecific antibodies, CRS was observed in nearly half of patients and mostly low grade, incidence of ICANS was mostly below 10%, with grade ≥ 3 events being rare, while infections and hematologic toxicities, particularly neutropenia, represented clinically relevant adverse events, with elevated susceptibility to viral, bacterial, and opportunistic infections, often exacerbated by hypogammaglobulinemia.

Frequently Asked Questions

How does Odronextamab target relapsed or refractory marginal zone lymphoma?
Odronextamab is a CD20xCD3 bispecific antibody designed to bridge CD20-expressing lymphoma cells with CD3-expressing T-cells. This dual engagement facilitates T-cell activation and redirects them to induce cytotoxicity against the malignant B-cells. Its mechanism aims to overcome resistance mechanisms often seen in relapsed or refractory settings.
What are the current treatment challenges in relapsed or refractory marginal zone lymphoma?
Patients with relapsed or refractory marginal zone lymphoma often face limited treatment options after initial therapies, particularly for those who are refractory to rituximab-based regimens. The disease can be indolent but recurrent, necessitating effective and durable therapies that minimize long-term toxicity. There is a significant unmet need for novel agents that can induce deep and lasting responses in this population.
What is the therapeutic rationale for bispecific antibodies in B-cell lymphomas like MZL?
Bispecific antibodies offer a novel immunotherapeutic approach by engaging both tumor cells and immune effector cells simultaneously. In B-cell lymphomas, CD20xCD3 bispecifics leverage the abundant expression of CD20 on malignant B-cells and the potent cytotoxic capabilities of T-cells. This targeted T-cell redirection aims to overcome immune evasion and induce robust anti-tumor responses.
What are key considerations for patient selection for novel therapies in relapsed or refractory MZL?
Patient selection for novel therapies in relapsed or refractory MZL involves assessing prior treatment history, disease burden, and overall fitness. Factors such as comorbidities, performance status, and potential for specific adverse events, like cytokine release syndrome, are crucial. Identifying patients most likely to benefit while managing potential risks is paramount for optimal outcomes.

References

  1. [1] Bravo Padros M, Conrado DJ et al.. Pharmacokinetics of Odronextamab, A Bispecific T-Cell-Engaging Antibody, in Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma. CPT: pharmacometrics & systems pharmacology. 2026 Jan. 41351218
  2. [2] Alig SK, Reinhardt HC et al.. [What is established in the treatment of diffuse large B-cell lymphoma?]. Innere Medizin (Heidelberg, Germany). 2025 Dec. 41125821
  3. [3] Bock AM, Nowakowski GS et al.. Bispecific Antibodies for Non-Hodgkin Lymphoma Treatment. Current treatment options in oncology. 2022 Feb. 35182296
  4. [4] Gordon MJ, Feng L et al.. Safety and efficacy of ibrutinib in combination with rituximab and lenalidomide in previously untreated follicular and marginal zone lymphoma: An open label, phase 2 study. Cancer. 2024 Mar 15. 37985359
  5. [5] Koyun D, Şahin U et al.. Real-World Efficacy and Safety of the Combination of Rituximab, Lenalidomide, and Ibrutinib in Patients with Relapsed and/or Refractory Non-Hodgkin Lymphoma. Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion. 2025 Jul. 40687457
  6. [6] Chakravarty A. Central Nervous System Manifestations of Cutaneous Lymphomas. Current neurology and neuroscience reports. 2025 Mar 25. 40131611
  7. [7] Cook JR, Amador C et al.. Transformations of marginal zone lymphomas and lymphoplasmacytic lymphomas: Report from the 2021 SH/EAHP Workshop. American journal of clinical pathology. 2023 Apr 26. 37186259
  8. [8] Zhao X, Bian H et al.. Clinicopathological characteristics and genomic profiling in patients with transformed lymphoma: a monocentric retrospective study. Annals of medicine. 2024 Dec. 39460552
  9. [9] Bannerji R, Arnason JE et al.. Odronextamab, a human CD20×CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial. The Lancet. Haematology. 2022 May. 35366963
  10. [10] Cheson BD, Morschhauser F et al.. Management of Adverse Events From the Combination of Rituximab and Lenalidomide in the Treatment of Patients With Follicular and Low-Grade Non-Hodgkin Lymphoma. Clinical lymphoma, myeloma & leukemia. 2020 Sep. 32303486
  11. [11] Fowler NH, Davis RE et al.. Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial. The Lancet. Oncology. 2014 Nov. 25439689
  12. [12] Martín García-Sancho A, Cabero-Martínez A et al.. Odronextamab: a bispecific antibody for follicular lymphoma. Expert opinion on investigational drugs. 2026 Jul. 42287116
  13. [13] Townsend W, Ghosh N et al.. Glofitamab in combination with immunochemotherapy in patients with relapsed/refractory B-cell non-Hodgkin lymphoma: Phase 1b dose-escalation study. British journal of haematology. 2026 Oct. 42608144
  14. [14] Patel K, Vose JM et al.. Pirtobrutinib, a highly selective, noncovalent (reversible) BTKi in R/R marginal zone lymphoma: phase 1/2 BRUIN study. Blood advances. 2026 Apr 14. 41544219
  15. [15] Sindel A, Al-Juhaishi T et al.. Marginal Zone Lymphoma: State-of-the-Art Treatment. Current treatment options in oncology. 2019 Dec 5. 31807935
  16. [16] Munoz J, Follows GA et al.. Copanlisib for the Treatment of Malignant Lymphoma: Clinical Experience and Future Perspectives. Targeted oncology. 2021 May. 33687623
  17. [17] Wang H, He Q et al.. [Efficacy and safety of bendamustine-rituximab combination therapy for newly diagnosed indolent B-cell non-Hodgkin's lymphoma and elderly mantle cell lymphoma: a multi-center prospective phase II clinical trial in China]. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi. 2023 Jul 14. 37749033
  18. [18] Becnel MR, Nastoupil LJ et al.. Lenalidomide plus rituximab (R(2) ) in previously untreated marginal zone lymphoma: subgroup analysis and long-term follow-up of an open-label phase 2 trial. British journal of haematology. 2019 Jun. 30919940
  19. [19] Danilov AV, Kambhampati Thiruvengadam S et al.. Indirect comparison of epcoritamab vs chemoimmunotherapy, mosunetuzumab, or odronextamab in follicular lymphoma. Blood advances. 2025 Aug 12. 40472301

Contact Us

📍

Address

350 Springfield Avenue,
Suite #200 Summit, NJ 07901

✉️

For General Inquiry

info@pienomial.com

Related Posts